CLINICAL_TRIALS
trial_result
· 2010-11-03
Clinical Trial Update: Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma [Phase 1]
Summary
A completed Phase 1 trial evaluating AVE1642, an anti-IGF1R monoclonal antibody, in patients with advanced multiple myeloma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sanofi | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED